PARP9

Across TCGA pan-cancer cohorts, PARP9 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PARP9 data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher PARP9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PARP9 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BLCA, LIHC, and UCEC are the cancer types where PARP9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.178	0.547	.004	15	view →
LIHC	OS	Median	III,IV	0.270	0.732	.021	12	view →
UCEC	OS	Median	All	0.976	0.863	.022	10	view →
SKCM	DFS	Median	II,III,IV	0.904	0.661	.009	10	view →
BRCA	OS	Median	All	0.817	0.963	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PARP9–BLCA (OS)

Open the BLCA breakdown →